| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4004274 | American Journal of Ophthalmology | 2009 | 17 Pages |
Abstract
The PrONTO Study using an OCT-guided variable-dosing regimen with intravitreal ranibizumab resulted in VA outcomes comparable with the outcomes from the phase III clinical studies, but fewer intravitreal injections were required.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Geeta A. Lalwani, Philip J. Rosenfeld, Anne E. Fung, Sander R. Dubovy, Stephen Michels, William Feuer, Janet L. Davis, Harry W. Jr, Maria Esquiabro,